Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16831964 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL16832019 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL16832018 | 0.88 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL10375965 | 0.85 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL10375966 | 0.85 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL16852806 | 0.82 | TTR (0.56) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL16831650 | 0.79 | TUBB4A (0.51) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL16831652 | 0.79 | TUBB4A (0.51) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA12 | |
| SCHEMBL24569275 | 0.75 | PIK3CD (0.38) | KDM4EALDH1A1MAPK1LMNAMAPT | |
| SCHEMBL18195226 | 0.72 | TTR (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | KDM4E 1805/4885ALDH1A1 799/4885SMN1; SMN2 3477/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | KDM4E 1805/4885ALDH1A1 799/4885SMN1; SMN2 3477/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | KDM4E 1805/4885ALDH1A1 799/4885SMN1; SMN2 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.